Florian Meyer, Ina Schmitt, Volker F Wendisch, Nadja A Henke
{"title":"Response surface-based media optimization for astaxanthin production in <i>Corynebacterium glutamicum</i>.","authors":"Florian Meyer, Ina Schmitt, Volker F Wendisch, Nadja A Henke","doi":"10.3389/fbioe.2025.1516522","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Astaxanthin is a C40 carotenoid that is used in animal feeds or cosmetics. Due to its high antioxidant property it is used for, e.g., anti-aging formulations and due to its intense red color it is used, e.g., in animal feed. While about 95% of commercial astaxanthin is currently chemically synthesized from fossil sources, the interest in natural and sustainable astaxanthin is growing. <i>Corynebacterium glutamicum</i>, an attractive host used in large-scale processes, e.g., industrial amino acid production, has been engineered for astaxanthin production.</p><p><strong>Methods: </strong>Here, a design of experiment (DoE) approach was applied to optimize the standard minimal medium for astaxanthin production. The concentrations of carbon, nitrogen and phosphorus sources, magnesium, calcium, the iron chelator protocatechuic acid, the vitamin biotin, and the trace metals were varied and astaxanthin production was evaluated.</p><p><strong>Results and discussion: </strong>By increasing the concentration of iron and decreasing that of manganese especially, it was possible to increase astaxanthin titers from 7.9 mg L<sup>-1</sup>-39.6 mg L<sup>-1</sup> in a micro cultivation system and from 62 mg L<sup>-1</sup>-176 mg L<sup>-1</sup> in a fed-batch fermentation.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1516522"},"PeriodicalIF":4.3000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11933003/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1516522","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Astaxanthin is a C40 carotenoid that is used in animal feeds or cosmetics. Due to its high antioxidant property it is used for, e.g., anti-aging formulations and due to its intense red color it is used, e.g., in animal feed. While about 95% of commercial astaxanthin is currently chemically synthesized from fossil sources, the interest in natural and sustainable astaxanthin is growing. Corynebacterium glutamicum, an attractive host used in large-scale processes, e.g., industrial amino acid production, has been engineered for astaxanthin production.
Methods: Here, a design of experiment (DoE) approach was applied to optimize the standard minimal medium for astaxanthin production. The concentrations of carbon, nitrogen and phosphorus sources, magnesium, calcium, the iron chelator protocatechuic acid, the vitamin biotin, and the trace metals were varied and astaxanthin production was evaluated.
Results and discussion: By increasing the concentration of iron and decreasing that of manganese especially, it was possible to increase astaxanthin titers from 7.9 mg L-1-39.6 mg L-1 in a micro cultivation system and from 62 mg L-1-176 mg L-1 in a fed-batch fermentation.
期刊介绍：
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
